Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib vs investigator-selected TKI in newly diagnosed Ph+ CML-CP (Japan, Phase III)
jRCT2021210060Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of asciminib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Major Molecular Response (MMR) at Week 48 (overall) and Major Molecular Response (MMR) at Week 48 (imatinib-stratum). Started Dec 2021; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2021210060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210060.